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Stlmmsl'y 
Vitamin A (retinol) is an essential cofactor for growth of B lymphocytes in culture and for activation 
ofT lymphocytes  by antigen receptor-mediated signals. 14-hydroxy-4,14-retro-retinol  (14-HKR) 
a metabolite of retinol, has been implicated as the intraceUular mediator of this effect. Anhydroretinol 
(AR) is a retinol derivative with retro structure produced in activated  human B lymphocytes 
and the insect cell lines SF 21 and Schneider $2. AK reversibly inhibits retinol- and 14-HKK- 
dependent effects and blocks B  lymphocyte proliferation as well as  activation of resting T 
lymphocytes. The intraceUular signaling pathway blocked by AK in T cell activation is distinct 
from the calcineurin/interleukin 2 pathway inhibitable by cyclosporine  A  or FK-506. 
I 
'n vertebrates, many different processes as diverse as growth, 
. vision, and reproduction are vitamin A  (retinol) depen- 
dent (1). Retinol is the source for a number of metabolites 
that are adapted to specific functions, such as 11.cis retinal 
in vision (2) or 9-cis and all-trans retinoic acid for differentia- 
tion of a,number of cellular systems (3). The general mecha- 
nism of action of retinoids presumably is connected with their 
specific binding proteins. The retinoic acids serve as ligands 
for a group of nuclear receptor molecules termed RAK and 
RXK (4-6). These receptors represent transcription factors 
akin to the much larger family of steroid receptors (7). They 
have in common a modular structure that includes zinc finger- 
and ligand-binding domains. On the basis of genetic homol- 
ogies, a number of "orphan" receptors have recently been 
identified, so-caUed because of similar modular design, but 
lack of knowledge of the respective ligands.  Thus it is pos- 
sible that a large family of lipophilic molecules evolved from 
primordial compounds in parallel to the superfamily of ste- 
roid/retinoic acid receptors. 
Retinol can be regarded as a pro-hormone from which sev- 
eral effector molecules are derived. In whole animal experi- 
ments, retinol could not be replaced by retinoic acid to re- 
verse all symptoms of vitamin A deficiency (8). For instance, 
neither the profound immune dysfunction nor male sterility 
resulting from vitamin A  deprivation was ameliorated by 
retinoic acid repletion (9-11). Thus other metabolites of ret- 
inol, effective in the development of lymphoid cells and sper- 
matocytes, have long been postulated. The first such effector 
molecule, 14-hydroxy-retro-retinol  (14-HRK) 1 (12), was dis- 
covered  among the endogenous retinoids of normal and 
transformed lymphocytes. It had the outstanding ability to 
substitute for retinol in its role as a required cofactor for acti- 
vation and growth of lymphocytes in culture, and is presumed 
to be the active mediator of the retinol effect in this system 
(13). 14-HRR has been found in a variety of tissues and spe- 
des extending as far back in evolution as fruit flies (our un- 
published results). This remarkable conservation might point 
to a central physiological function. In fact, many transformed 
lymphoid cells deprived of 14-HRR after retinol withdrawal 
cease to proliferate  and die (14, 15). However, at this time 
the mechanism of action of 14-HRR is unknown, although 
by analogy to the retinoic adds, the role as a ligand for a 
cytoplasmic or nuclear receptor is more than likely. This con- 
cept received strong support in this report with the discovery 
of a second endogenous retinoid of lymphocytes with retro 
structure, anhydroretinol (AR), which functions as a com- 
petitive inhibitor of 14-HRR and which might bind to the 
same receptor protein. 
1 Abbreviations used in this  paper: AK, anhydroretinol;  CRABP-1, cellular 
retinoic acid binding protein 1; CRBP-1, cellular retinol binding protein 
1; 14-HRR, 14-hydroxy-retro-retinol; ITBL, insulin,  transferrin,  linoleic 
acid, and bovine albumin  medium;  RBP,  retinol binding protein. 
675  J. Exp.  Med.  ￿9  The Rockefeller University  Press ￿9 0022-1007/93/08/0675/06  $2.00 
Volume 178  August 1993  675-680 Materials and Methods  A 
Cells and Cell Cultures.  The lymphoblastoid cell line 5/2 was  2sooo- 
derived in our laboratory from a healthy volunteer by transforma- 
tion with EBV. It was propagated in RPMI 1640 medium sup- 
plemented with 7% fetal bovine serum. Where indicated as sernm- 
flee culture,  the medium contained RPMI 1640 supplemented with  12so0- 
8  x  10 -7 M insulin,  7  x  10 -s M transferrin,  2  x  10 -4 M linoleic 
acid, 2  x  10-6 M delipidated  BSA, 2 mM t-glutamine, 1 mM so- 
dium pyruvate, and antibiotics (referred to as ITBL medium). In- 
vertebrate cell lines were obtained as follows: $2M3 from Dr. Robert 
DeLotto (Memorial Sloan-Kettering Cancer Center); and SF 21  7sooo~ 
and SF 9 from Dr. Philip W.  Majerus (Washington  University,  B 
St. Louis, MO). They were grown in Grace's insect medium/10% 
FCS at 26~  I= 
Retinoids.  All-trans-retinol was purchased from Sigma Chemical  e, 
Co.  (St.  Louis,  MO),  [aH]retinol was purchased from Dupont/  "-" 3s000- 
New England Nuclear (Boston, MA). AR was isolated from the  -r- 
cell line SF 21 as follows:  10 liters of cell suspension were incubated  ~' 
with  10 -s M  retinol overnight at 26~  The cell pellet was ex- 
tracted by the method of McClean et al. (16). The extract was chro-  s0o0o-" 
matographed on a preparative Cls HPLC column using a water/  C 
methanol/chloroform gradient. The three cis-trans isomers of AR 
eluting at 92% methanol/8%  water were pooled. A second run 
on an analytical Cls column fielded pure AR.  Its UV spectrum 
showed a characteristic  vibronic fine structure with maxima at 351,  asoo0- 
368, and 390 nm (17, 18). Mass spectroscopy and proton nuclear 
magnetic resonance confirmed the structure (Derguini, F., manu- 
script in preparation). 
Synthetic AR produced by acid catalyzed dehydration ofall-trans 
retinol (18) was used for bioassays. Synthetic AR was purified by  o 
the same HPLC chromatographic procedure described above.  14- 
hydroxy-retro-retinol  was isolated from pellets of HeLa cells as de- 
scribed (12). 
B CeUProliferation and T CellActivation Assays.  These were car- 
ried out as described in detail by Garbe et al.  (13). 
Retinoid Binding Proteins.  Human cellular retinol binding pro- 
tein  1  (CRBP-1)  and  cellular  retinoic  acid  binding  protein  1 
(CRABP-1) were gifts from Drs. W. S. Blaner (Columbia Univer- 
sity) and J. Napoli (State University of New York, Buffalo,  NY), 
respectively. 
Results and Discussion 
Among the metabolites of retinol extracted from B lym- 
phoblastoid  cells and  chromatographically  separated on  an 
HPLC Cls column with a water/methanol/chloroform  gra- 
dient  (Fig.  1 C),  we noted the presence of a retinoid with 
relatively hydrophobic properties,  eluting  in  the particular 
gradient system used at minute 29.  Two minor companions 
at minutes 28 and 27 are likely cis/trans isomers of the same 
compound.  The three peaks exhibited  nearly identical  UV 
absorption spectra with vibronic fine structure and maxima 
at 351,  368,  and 390 nm indicating a retro-retinoid  skeleton 
with six double bonds. A chance observation of overproduc- 
tion  of an identical  retinoid  in  a  subline  of the Drosophila 
$2M3 cell line allowed us to isolate this retinoid in quantity 
and to determine its structure  as AR on the basis of mass 
and nuclear magnetic resonance spectroscopy, as will be de- 
scribed elsewhere (Derguini,  F., manuscript in preparation) 
(see structure 3 in Fig.  1). AR synthesis is dependent  on an 
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Figure  1.  High pressure liquid chromatography of retinoids from in- 
sect SF 9 (A), SF 21 (B), and human lymphoblastoid 5/2 cells (C). Cells 
(10  x  106 cells in 10 ml of RPMI/7% FCS medium or Grace's insect 
medium/7% FCS) were incubated with 10/zCi [3H]retinol; sp act, 49.3 
Ci/mmol. After 4 h (.4 and B) or 16 h (C), retinoids were extracted from 
the washed cell pellet according to the procedure of McClean et al. (16). 
Retinoids were separated on an analytical Cls reversed-phase  column and 
detected with an on-line scintillation counter using the methodology de- 
scribed by Buck et al. (12). AR was the predominant metabolite in SF 
21 (B) but was undetectable in SF 9 cells (A), a subclone of SF 21. Lym- 
phoblastoid 5/2 also produced AR (C). Note that the small shifts in peaks 
are due to use of different Cls columns, each one, however, calibrated by 
standards. (D) Structures  of retinol,  14-hydroxy-retro-retinol, and an- 
hydroretinol. The peak eluting at minute 29 is the all-trans  AR, whereas 
the companion peaks at minutes 27 and 28 represent  c/s-isomers.  All homers 
yield spectra with characteristic vibronic fine structure similar to the spec- 
trum of all-trans AR (E). 
active metabolic state. It does not occur when cells are kept 
at  +4~  fixed with glutaraldehyde, or energetically blocked 
with  sodium azide (data not  shown).  Moreover,  the SF 21 
cell line of Spodopterafrugiperda produces AR as the predom- 
inant retinol metabolite, whereas a subclone of this line, SF 
9,  does not produce detectable amounts of AR.  Thus,  AR 
does not appear to arise from spontaneous dehydration but 
is enzymatically derived.  In the test  tube,  however,  AR is 
easily  synthesized  from  retinol  by acid-catalyzed  dehydra- 
tion (18). 
AR was in fact the first retro-retinoid discovered in nature. 
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Figure 2.  AR as reversible inhibitor of B lymphocyte proliferation. AR was produced from all-trans retinol by hydrochloric acid catalyzed dehydration 
as described (18), and the all.trans isomer was purified to homogeneity by reversed-phase high pressure liquid chromatography. Human B ]ymphoblastoid 
cells (e.g., cell line 5/2) were cuhured in medium RPM1 1640 with 7% FCS. On the day of the assay, cells were washed and transferred to serum-free 
medium, RPM1 1640 supplemented with ITLB medium as described (13). Test reagents at indicated concentrations  were added to triplicate cultures 
of 5  x  103 cells/well in 96-well plates (final volume of 200 #l/well) and cell proliferation tested 1 (B-D) or 3 d later (A) by [3H]thymidine incorpora- 
tion into DNA. The agonists used were all-trans retinol (A),  14-HRR (B), and FCS (C).  Serum contains 1-2  x  10 -6 M all-trans retinol. (D) Three 
additional  human lymphoblastoid  cell lines, Horn 2, Jest,  and Ducal were tested under the conditions specified for A. 
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Figure  3.  AR as antagonist  of induction of thymocyte proliferation,  but not of Ib2 production. Murine thymocytes (2  x  10S/well  in triplicates) 
were cultured  in ITLB medium in 96-well plates coated with 10/~g/ml  anti-CD3e  mAb (24) as described  (13).  The retinoid agonists,  retinol (A) 
or 14-HRR (B), were added along with AR at different doses in checkerboard fashion.  Cell proliferation  was tested on day 3 by [3H]thymidine incor- 
poration into DNA. (C) The time of addition  of AR. at different concentrations  was varied from 0 to 54 h after initiation of cultures with anti-CD3e 
plus 2  x  10 -6 M retinol. The results of cell proliferation assays performed at 72 h are shown. Culture supernatants of anti-CD3e plus retinol/AR-stimu- 
lated thymocytes were tested after 18 h for their II;2 content by the ability  to stimulate the cell line CTLL (25).  CTLL proliferation  was measured 
by [3H]thymidine incorporation  into DNA  (D). SD of triplicate  measurements were <10%.  The CTLL cell line was tested in the presence of rlL-2 
for responsiveness  to retinol and AR over broad dose ranges  and found independent  of either retinoid (data not shown). 
It  was  found  in  fish  and  whale  liver  oils  in  1939  (19)  and 
later in transformed mouse fibroblasts (20). Its biological func- 
tion,  however,  remained obscure.  Owing  to the close struc- 
tural  similarity  to  14-HRR,  we  tested  the effect  of AR.  on 
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proliferation  of lymphoblastoid  B  cells. AR  did not support 
B  cell proliferation  on its own  (Fig.  2  A).  On  the contrary, 
AR  proved  to behave  as a competitive  inhibitor,  leading  to 
cell death.  The inhibitory effect was dose dependent,  but de- pended on the retinol status of the cultures and on the time 
of measurement. Inhibition was most pronounced, requiring 
a minimum dose of AlL of 3  x  10- 7 M and a culture time 
of 3 d to essentially kill all cells, when no other retinoid was 
added to the medium (Fig. 2 A), whereas  1 d after onset 
of culture complete inhibition required a 10-fold-higher dose 
of AR (Fig. 2 B). The inhibitory effect of AR was counter- 
acted effectively by retinol (Fig. 2 A) or 14-HRR (Fig. 2 
B), and in both cases, the relative concentrations of agonist 
(retinol or 14-HRR) and antagonist  (AR) determined the 
outcome, i.e., proliferation versus cell death. The inhibition 
curves shown are typical for reversible inhibition of a phar- 
macological  agent and imply competition for a common 
receptor molecule. AR was also capable of  reversibly  inhibiting 
lymphoblastoid B cells grown under more physiological con- 
ditions in serum-containing medium (Fig. 2 C). Several  other 
randomly selected  lymphoblastoid B cell lines were also found 
to be sensitive to inhibition with AR (Fig. 2 D). So far we 
have encountered no exception among many more lines tested, 
including freshly EBV-transformed B lymphocytes, indicating 
a general dependence among B cells on 14-HRR as growth- 
promoting agonist and corresponding susceptibility to AR 
as an antagonist. 
Activation of  resting thymocytes by TClL-generated signals 
in serum-free medium was previously shown to be depen- 
dent on retinoid cofactors, retinol, or 14-HRR (13). To test 
whether AR would interfere with this process as well, mu- 
rine thymocytes  were stimulated in ITLB medium with im- 
mobilized anti-CD3e antibody and retinol or 14-HRlL  as 
cofactors, and various concentrations of AR. Inhibition of 
thymocyte  activation was pronounced, depending on the rel- 
ative concentrations of agonist (i.e., retinol or 14-HlLR) and 
AR, as illustrated by the series of dose-response  curves in 
Fig. 3, A and B. The interrelationship  between agonist and 
antagonist  was comparable to that observed in B lympho- 
cytes. AR not only prevented the activation of thymocytes, 
but was also able to reduce the thymidine uptake of cycling 
thymocytes if given 2 d after activation  (Fig. 3 C). 
Cyclosporine  A and FK 506 block IL-2 release and the 
expression  of IL-2 receptor and prevent  the activation  of 
CD4 + T lymphocytes (21, 22). We knew from previous un- 
published work that both IL-2 production and IL-2 receptor 
expression were unaffected  by the presence  or absence  of  retinol 
or 14-HRR. Therefore,  as expected, AIL did not interfere 
with IL-2 release, as shown in Fig. 3 D. This is an important 
control experiment to indicate that the AlL effect on prolifer- 
ation is not due to generalized toxicity. 
A common feature in the physiology of retinoids  is the 
use of intracellular and extracellular binding proteins, often 
specialized for particular retinoids, for protection against ox- 
idative degradation and for transport. All three retinoids tested 
bind to RBP of plasma and to CRBP-1 (Table 1), but the 
affinities of retinol and AlL are 10-fold higher than those of 
14-HRlL (23). Given these circumstances, competitive inhi- 
bition at the level of CRBP-I may explain the retinol-AlL 
antagonism. For instance, if the CRBP-1/retinol complex were 
required for 14-HRR biosynthesis, its disruption by the AlL 
antagonist might interfere with this step. However, we found 
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Table  1.  Dissociation Constants of Retinoids Bound to 
Extra- or Intracellular Binding Proteins 
Dissociation constant 
Retinoid  RBP  CRBP-1  CRABP-1 
/~M 
Retinol  0.15  0.013  No binding 
14-HRR  0.12  0.21  No binding 
AR  0.020  0.023  No binding 
No binding, no significant binding could be detected. 
Dissociation constants of retinoids to serum RBP, CRBP-1, and CRABP-1 
were measured by fluorimetric titration. Apo-protein (1-3 ~M) was titrated 
with the appropriate aU-trans-retinoid  dissolved in ethanol, and the titra- 
tion was followed by measuring the increase in the fluorescence of the 
retinoids upon binding. Reaction mixtures included 150 mM NaC1, 0.1 
mM DTT, and 25 mM Hepes, pH, 7.0 and 7.4, respectively. Retinoid 
fluorescence was measured at the excitation and emission maxima for the 
different retinoids: i.e., excitation, 330, 350, and 368 nm; emission, 480, 
515, and 570 nm for retinol, 14-HRR, and AR, respectively. Data ana- 
lyses were performed as described by Cogan et al. (26). Human RBP was 
purified from  human serum by means of a transthyretin column (27). 
no change in the metabolic rate of 14-HRR synthesis from 
3H-labeled retinol in the presence of a 100-fold excess of AlL 
(data not shown). Moreover, the promyelocytic  cell line HL- 
60 fails to express CRBP-1 but is nonetheless susceptible to 
reversible growth inhibition by AR (Eppinger, T., J. Buck, 
and U. H~-amerling, unpublished observations). We conclude 
that CRBP-1 is not involved in the biological retinol-AR 
antagonism.  Moreover,  the facts  that  14-HlLR  binds  to 
CRBP-1 with appreciably lower affinity (Table 1) and that 
AR also reversibly inhibits cultures of lymphocytes when 14- 
HRR is provided as an agonist  (Figs. 2 B and 3, B) imply 
antagonism  at  a point downstream of,  or in addition to, 
CRBP-1. A separate 14-HRR/AR binding protein/receptor, 
as yet to be defined, is inferred. 
The demonstration that AR acts as antagonist to retinol 
and, especially,  to 14-HRR contributes to the understanding 
of the mechanism of action of these retinoids. First, the phar- 
macological reversibility is best explained by competition of 
two  structurally closely related  compounds for the same 
receptor. Second, 14-HRR and AR occur in mammalian and 
insect cells, thus suggesting conservation of a complex family 
of  retro-retinoids  over a long evolutionary period. Third, AR 
has been observed by us as a natural product of B lympho- 
cytes and therefore the positive signaling action of 14-HRR 
and the negative one of AR may be meaningful for lympho- 
cyte physiology. To our knowledge, 14-HRR and AR con- 
stitute the first naturally occurring agonist/antagonist pair 
of retinoids (or other small lipophilic messenger molecules) 
to be described. Fourth, the retro-retinoid pathway is essen- 
tial for T cell activation, but appears to operate independently 
of the calcineurin/IL-2 pathway. AR might presage the de- 
velopment of new types of immunosuppressive  and/or an- 
tiproliferative  agents. We are greatly indebted to Professor Koji Nakanishi (Department of Chemistry, Columbia University) 
for discussion  and invaluable  support of this work. 
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